Skip to main content

Advertisement

SpringerLink
Log in

Policy progress for physician treatment of opiate addiction

  • Health Policy
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

Medical treatment of heroin addiction with methadone and other pharmacotherapies has important benefits for individuals and society. However, regulatory policies have separated this treatment from the medical care system, limiting access to care and contributing to the social stigma of even effective addiction pharmacotherapy. Increasing problems caused by heroin addiction have added urgency to the search for policies and programs that improve the access to and quality of opiate addiction treatment. Recent initiatives aiming to reintegrate methadone maintenance and other addiction pharmacotherapies into medical practice may promote both expanded treatment capacity and increased physician expertise in addiction medicine. These initiatives include changes in federal oversight of the opiate addiction treatment system, the approval of physician office-based methadone maintenance programs for stabilized patients, and federal legislation that could enable physicians to treat opiate addiction with new medications in regular medical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Office of National Drug Control Policy. National drug control strategy. Washington, DC: Office of National Drug Control Policy; 2000.

    Google Scholar 

  2. Solet D, Hagan H, Nakaguwara J, Plough A, Ball JK. Unintentional opiate overdose deaths — King County, Washington, 1990–1999. Morb Mortal Wkly Rep. 2000;49:636–8.

    Google Scholar 

  3. Oxman GL, Kowalski S, Drapela L, et al. Heroin overdose deaths — Multinomah County, Oregon, 1993–1999. Morbid Mortal Wkly Rep. 2000;49:633–6.

    Google Scholar 

  4. Drug Abuse Warning Network Annual Medical Examiner Data 1999. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Web site. Available at: http://www.samhsa.gov/oas/DAWN/99me_annual.pdf. Accessed March 15, 2002.

  5. Bach PB, Lantos J. Methadone dosing, heroin affordability, and the severity of addiction. Am J Public Health. 1999;89:662–5.

    Article  PubMed  CAS  Google Scholar 

  6. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001; 61:195–206.

    Article  PubMed  CAS  Google Scholar 

  7. Meadows M. Prescription drug use and abuse. FDA Consum. 2001;35:18–24. Available at: http://www.fda.gov/fdac/features/2001/501_drug.html. Accessed March 15, 2002.

    Google Scholar 

  8. Community Epidemiologic Work Group. Epidemiologic Trends in Drug Abuse: Advance Report. Rockville, Md: National Institute on Drug Abuse; 2001.

    Google Scholar 

  9. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280:1936–43.

    Article  Google Scholar 

  10. Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA. 2000;283:1337–9.

    Article  PubMed  CAS  Google Scholar 

  11. Musto DF. The American Disease: Origins of Narcotic Control. Expanded ed. New York: Oxford University Press; 1987.

    Google Scholar 

  12. Massing M. The Fix. New York: Simon and Schuster; 1998.

    Google Scholar 

  13. Rettig RA, Yarmolinsky A, eds. Federal Regulation of Methadone Treatment. Washington, D.C: National Academy Press; 1995.

    Google Scholar 

  14. Spunt B, Hunt D, Lipton D, Goldsmith D. Methadone diversion: a new look. J Drug Issues. 1986;18:569–83.

    Google Scholar 

  15. Barrett DH, Luk AJ, Parrish RG, Jones TS. An investigation of medical examiner cases in which methadone was detected, Harris County, Texas, 1987–1992. J Forensic Sci. 1996;41:442–8.

    PubMed  CAS  Google Scholar 

  16. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193:80–4.

    Google Scholar 

  17. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7: 249–56.

    Article  PubMed  CAS  Google Scholar 

  18. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485–8.

    Article  PubMed  CAS  Google Scholar 

  19. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221–6.

    Article  PubMed  CAS  Google Scholar 

  20. Ball J. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcomes. New York: Springer-Verlag; 1991.

    Google Scholar 

  21. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust. 1991;154:195–9.

    PubMed  CAS  Google Scholar 

  22. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119:23–7.

    PubMed  CAS  Google Scholar 

  23. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate-vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000–5.

    Article  PubMed  CAS  Google Scholar 

  24. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000; 283:1303–10.

    Article  PubMed  CAS  Google Scholar 

  25. Hubbard RL, Marsden ME, Rachel JV. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill: University of North Carolina Press; 1989.

    Google Scholar 

  26. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260:3025–9.

    Article  PubMed  CAS  Google Scholar 

  27. Stimmel B, Kreek MJ. Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med. 2000;67: 375–80.

    PubMed  CAS  Google Scholar 

  28. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689–95.

    Article  PubMed  CAS  Google Scholar 

  29. D’Aunno T, Vaughn TE. Variations in methadone treatment practices. Results from a national study. JAMA. 1992;267: 253–8.

    Article  PubMed  CAS  Google Scholar 

  30. Cooper JR. Ineffective use of psychoactive drugs. Methadone treatment is no exception. JAMA. 1992;267:281–2.

    Article  PubMed  CAS  Google Scholar 

  31. Parrino MW. State Methadone Treatment Guidelines. Treatment improvement protocol (TIP) series no 1. Rockville, Md: Center for Substance Abuse Treatment; 1993.

    Google Scholar 

  32. Wilson P, Watson R, Ralston GE. Methadone maintenance in general practice: patients, workload, and outcomes. BMJ. 1994; 309:641–4.

    PubMed  CAS  Google Scholar 

  33. Peters AD, Reid MM. Methadone treatment in the Scottish context: outcomes of a community-based service for drug users in Lothian. Drug Alcohol Depend. 1998;50:47–55.

    Article  PubMed  CAS  Google Scholar 

  34. Hutchinson SJ, Taylor A, Gruer L, et al. One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. Addiction. 2000;95:1055–68.

    Article  PubMed  CAS  Google Scholar 

  35. Brewer C. Recent developments in maintenance prescribing and monitoring in the United Kingdom. Bull NY Acad Med. 1995;72: 359–70.

    CAS  Google Scholar 

  36. Gruer L, Wilson P, Scott R, et al. General practitioner-centred scheme for treatment of opiate-dependent drug injectors in Glasgow. BMJ. 1997;314:1730–5.

    PubMed  CAS  Google Scholar 

  37. Klingemann HK. Drug treatment in Switzerland: harm reduction, decentralization and community response. Addiction. 1996;91: 723–36.

    Article  PubMed  CAS  Google Scholar 

  38. Caplehorn J, Batey R. Methadone maintenance in Australia. J Drug Issues. 1992;22:661–79.

    Google Scholar 

  39. Byrne A, Wodak A. A census of patients receiving methadone treatment in a general practice. Addict Res. 1996;3:341–9.

    Google Scholar 

  40. College of Physicians and Surgeons of Ontario. Methadone Maintenance Guidelines. Toronto: The College of Physicians of Ontario; 1996.

    Google Scholar 

  41. World Health Organization Programme on Substance Abuse Substitution Project. Report of WHO Consultation, Geneva, 15–9 May 1995. Geneva: World Health Organization; 1996.

    Google Scholar 

  42. Morrison C. Obstetric liason in drug dependency. Addict Res. 1995;3:93–101.

    Google Scholar 

  43. Greenwood J. Persuading general practitioners to prescribe — good husbandry or a recipe for chaos? Br J Addict. 1992;87:567–75.

    Article  PubMed  CAS  Google Scholar 

  44. Greenwood J. Creating a new drug service in Edinburgh. BMJ. 1990;300:587–9.

    PubMed  CAS  Google Scholar 

  45. Hall D. The Demand for Methadone Maintenance Treatment in Australia. National Drug and Alcohol Research Center, Technical Report No. 28. Sydney, Australia: National Drug and Alcohol Research Center; 1995.

    Google Scholar 

  46. Ward J, Mattick RP, Hall D. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Harwood Academic Publishers; 1998.

    Google Scholar 

  47. Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy. JAMA. 2000;283:1343–8.

    Article  PubMed  CAS  Google Scholar 

  48. Drummer OH, Opeskin K, Syrjanen M, Cordner SM. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol. 1992;13: 346–50.

    PubMed  CAS  Google Scholar 

  49. Strang J, Sheridan J. Methadone prescribing to opiate addicts by private doctors: comparison with NHS practice in southeast England. Addiction. 2001;96:567–76.

    Article  PubMed  CAS  Google Scholar 

  50. Fountain J, Strang J, Gossop M, Farrell M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction. 2000;95:393–406.

    Article  PubMed  CAS  Google Scholar 

  51. Substance Abuse and Mental Health Services Administration. Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction; Final Rule. Fed Regist. 2001;66:4075–102.

    Google Scholar 

  52. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000; 343:1290–7.

    Article  PubMed  CAS  Google Scholar 

  53. Glanz M, Klawansky S, McAullife W, Chalmers T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials. Am J Addict. 1997;6:339–49.

    Article  PubMed  CAS  Google Scholar 

  54. Salsitz EA, Joseph H, Frank B, et al. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice—a summary report (1983–1998). Mt Sinai J Med. 2000;67:388–97.

    PubMed  CAS  Google Scholar 

  55. Schwartz RP, Brooner RK, Montoya ID, Currens M, Hayes M. A 12-year follow-up of a methadone medical maintenance program. Am J Addict. 1999;8:293–9.

    Article  PubMed  CAS  Google Scholar 

  56. Senay EC, Barthwell A, Marks R, Bokos PJ. Medical maintenance: an interim report. J Addict Dis. 1994;13:65–9.

    Article  PubMed  CAS  Google Scholar 

  57. Fiellin DA, O’Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001;286:1724–31.

    Article  PubMed  CAS  Google Scholar 

  58. Lepay D, Clark HW. Federal Advisory on Methadone Medical Maintenance Exemptions. Rockville, Md: U.S. Department of Health and Human Services; 2000.

    Google Scholar 

  59. San Francisco Department of Public Health. A Program for Physician Prescription of Methadone in San Francisco. San Francisco, Calif: San Francisco Department of Public Health; 1999. Available at: http://www.dph.sf.ca.us/Reports/methrep.pdf. Accessed March 15, 2002.

    Google Scholar 

  60. Drucker E, Hartel D, Tuchman E, Bonuck K, Vavaglakis P, McCarthy W. Office Based Methadone Prescribing In Primary Care: Results of a Randomized Clinical Trial of Safety and Efficacy. San Juan, Puerto Rico: College on Problems of Drug Dependence; 2000.

    Google Scholar 

  61. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475–86.

    Article  PubMed  CAS  Google Scholar 

  62. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54:713–20.

    PubMed  CAS  Google Scholar 

  63. O’Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105:100–5.

    Article  PubMed  CAS  Google Scholar 

  64. Fhima A, Henrion R, Lowenstein W, Charpak Y. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). Ann Med Interne (Paris). 2001;152(Suppl 3):IS26–36.

    Google Scholar 

  65. Vignau J, Brunelle E. Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results. Eur Addict Res. 1998; 4(Suppl 1):24–8.

    Article  PubMed  Google Scholar 

  66. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction. 2001; 96:267–72.

    Article  PubMed  CAS  Google Scholar 

  67. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA. 2001;285:45.

    Article  PubMed  CAS  Google Scholar 

  68. Saitz R, Mulvey KP, Plough A, Samet JH. Physician unawareness of serious substance abuse. Am J Drug Alcohol Abuse. 1997;23: 343–54.

    PubMed  CAS  Google Scholar 

  69. Hasin DS, Grant BF, Dufour MG, Endicott J. Alcohol problems increase while physician attention declines. 1967 to 1984. Arch Intern Med. 1990;150:397–400.

    Article  PubMed  CAS  Google Scholar 

  70. Stimmel B. Appropriate training in alcohol and substance abuse for primary care physicians: defining the problem. In: Sirica C, ed. Training about Alcohol and Substance Abuse for All Primary Care Physicians. A Conference Sponsored by the Josiah Macy, Jr. Foundation, chaired by David C. Lewis, Phoenix, Arizona, October 2–5, 1994. New York: Josiah Macy, Jr. Foundation; 1995:249–74.

    Google Scholar 

  71. Fiellin DA, Storti SA, Schottenfeld RS, Biscoe JD, Pantalon MV, O’Connor PG. Methadone medical maintenance: a training and resource guide for office-based physicians. Vol. 2001: New England Addiction Technology Transfer Center; 2000. Available at http://www.caas.brown.edu/ATTC-NE/pubs/OBOT/. Accessed 11/24/01.

Download references

Author information

Authors and Affiliations

  1. Received from the Division of General Internal Medicine, Harborview Medical Center, Department of Medicine, and the Alcohol and Drug Abuse Institute, University of Washington, Seattle, Wash

    Joseph O. Merrill MD, MPH

Authors
  1. Joseph O. Merrill MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph O. Merrill MD, MPH.

Additional information

This work was assisted by a grant from the Robert Wood Johnson Foundation Substance Abuse Policy Research Program.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merrill, J.O. Policy progress for physician treatment of opiate addiction. J GEN INTERN MED 17, 361–368 (2002). https://doi.org/10.1007/s11606-002-0041-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-002-0041-6

Key Words

Search

Navigation